97 related articles for article (PubMed ID: 16890381)
1. Are HER1/EGFR interactions with ligand free HER2 related to the effects of HER1-targeted drugs?
Kurbel S
Med Hypotheses; 2006; 67(6):1355-7. PubMed ID: 16890381
[TBL] [Abstract][Full Text] [Related]
2. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
[TBL] [Abstract][Full Text] [Related]
3. A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer.
Eladdadi A; Isaacson D
Bull Math Biol; 2008 Aug; 70(6):1707-29. PubMed ID: 18648887
[TBL] [Abstract][Full Text] [Related]
4. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients.
Thøgersen VB; Sørensen BS; Poulsen SS; Orntoft TF; Wolf H; Nexo E
Cancer Res; 2001 Aug; 61(16):6227-33. PubMed ID: 11507076
[TBL] [Abstract][Full Text] [Related]
5. Role of HER2/neu in tumor progression and therapy.
Ménard S; Casalini P; Campiglio M; Pupa SM; Tagliabue E
Cell Mol Life Sci; 2004 Dec; 61(23):2965-78. PubMed ID: 15583858
[TBL] [Abstract][Full Text] [Related]
6. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
[TBL] [Abstract][Full Text] [Related]
7. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
8. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
Zhao W; Zhang Q; Kang X; Jin S; Lou C
Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
[TBL] [Abstract][Full Text] [Related]
9. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
[TBL] [Abstract][Full Text] [Related]
10. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
11. Single-molecule study of lateral mobility of epidermal growth factor receptor 2/HER2 on activation.
Xiao Z; Ma X; Jiang Y; Zhao Z; Lai B; Liao J; Yue J; Fang X
J Phys Chem B; 2008 Apr; 112(13):4140-5. PubMed ID: 18324805
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
[TBL] [Abstract][Full Text] [Related]
13. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
14. Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.
Fink-Retter A; Gschwantler-Kaulich D; Hudelist G; Mueller R; Kubista E; Czerwenka K; Singer CF
Oncol Rep; 2007 Aug; 18(2):299-304. PubMed ID: 17611648
[TBL] [Abstract][Full Text] [Related]
15. Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K; Sørensen BS; Poulsen SS; Forman A; Nexø E; Mogensen O
Gynecol Oncol; 2007 Jan; 104(1):158-67. PubMed ID: 16962163
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
17. Role of HER receptors family in development and differentiation.
Casalini P; Iorio MV; Galmozzi E; Ménard S
J Cell Physiol; 2004 Sep; 200(3):343-50. PubMed ID: 15254961
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
[TBL] [Abstract][Full Text] [Related]
19. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
20. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.
Biswas DK; Iglehart JD
J Cell Physiol; 2006 Dec; 209(3):645-52. PubMed ID: 17001676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
